Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

Novartis

Status: Completed

Conditions: Neovascular (Wet) Age-related Macular Degeneration

Study type: Observational

Funder types: Industry

Identifiers

NCT06184360

CRTH258A2014

Details and patient eligibility

About

This was a retrospective, observational cohort study. Data were analyzed from the Intelligent Research in Sight (IRIS) registry from October 8, 2019, through November 26, 2021, with a follow-up period of 12 months following the first brolucizumab injection (index date).

Enrollment: 2,079 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least 18 years old at the time of their first (index) injection of brolucizumab.
• Had documented neovascular age-related macular degeneration (nAMD) on or within 3 years before the index injection.
• Used only brolucizumab for at least 12 months (± 45 days) after the index injection, with at least 1 brolucizumab injection given within the first 6 months after the index injection and at least 1 additional brolucizumab injection given at 6-12 months after the index injection.

Exclusion criteria

• Had received any other anti-VEGF agent between the index injection and 12-month follow-up.
• Lacked information about the laterality of disease at the time of the index injection.
• Lacked visual acuity assessments on or within 30 days before the index injection or at 6, 9, and 12 months after the index injection (all of the latter ± 45 days).

Trial design

2,079 participants in 2 patient groups

Treatment-Experienced

Treatment-Naive